These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32358546)

  • 41. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C
    Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
    Cohen YC; Zuckerman T; Yeshurun M; Perez G; Magen H; Henig I; Levi I; Shargian L; Trestman S; Rouvio U; Naparstek E; Ganon-Elazar E; Avivi I; Ram R
    Ann Hematol; 2017 Feb; 96(2):271-278. PubMed ID: 28039512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
    Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
    Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose melphalan in 1 day versus over 2 days followed by autologous stem cell transplantation as consolidation treatment in patients with multiple myeloma.
    Aydin M; Tang MW; Wondergem MJ; de Leeuw DC; Wegman JJ; Biemond BJ; van de Donk NWCJ; Zweegman S; Meijer E; Nur E
    Br J Haematol; 2022 Mar; 196(6):e67-e70. PubMed ID: 34961917
    [No Abstract]   [Full Text] [Related]  

  • 46. [Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma].
    Zhang CY; Fu WJ; Xi H; Zhou LL; Jiang H; Du J; Fan JL; Li R; Jin LN; Zeng TM; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):313-6. PubMed ID: 23668203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
    Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
    Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma.
    Kazmi MA; Ahsan G; Schey SA
    Clin Lab Haematol; 2001 Apr; 23(2):125-9. PubMed ID: 11488852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
    Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
    Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
    Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.
    Ria R; Falzetti F; Ballanti S; Minelli O; Di Ianni M; Cimminiello M; Vacca A; Dammacco F; Martelli MF; Tabilio A
    Hematol J; 2004; 5(2):118-22. PubMed ID: 15048061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India.
    Garg V; Kodan P; Pushpam D; Bakhshi S; Kumar L; Sharma A; Gupta G; Gupta N
    Transfus Med; 2021 Oct; 31(5):377-382. PubMed ID: 34396610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country.
    Ali N; Adil SN; Shaikh MU
    Stem Cells Transl Med; 2015 Aug; 4(8):873-7. PubMed ID: 26032748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
    Samaras P; Blickenstorfer M; Siciliano RD; Haile SR; Buset EM; Petrausch U; Mischo A; Honegger H; Schanz U; Stussi G; Stahel RA; Knuth A; Stenner-Liewen F; Renner C
    Ann Hematol; 2011 Jan; 90(1):89-94. PubMed ID: 20706722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
    Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
    Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
    McDonald GB; Evans AT; McCune JS; Schoch G; Ostrow JD; Gooley TA
    Lancet Haematol; 2016 Nov; 3(11):e516-e525. PubMed ID: 27968820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.